, Tracking Stock Market Picks
Enter Symbol:
Penwest Pharmaceuticals Co. (PPCO) [hlAlert]

down 79.44 %

Penwest Pharmaceuticals Co. (PPCO) rated Buy

Posted on: Wednesday,  Jul 18, 2007  9:25 AM ET by Cowen & Co

Cowen & Co rated Buy Penwest Pharmaceuticals Co. (NASDAQ: PPCO) on 07/18/2007, when the stock price was $12.60.
Since then, Penwest Pharmaceuticals Co. has lost 79.44% as of 11/03/2010's recent price of $2.59.
If you would have followed this Cowen & Co's recommendation on PPCO, you would have lost 79.44% of your investment in 1204 days.

Penwest Pharmaceuticals Co. (Penwest) is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. The Company is developing A0001, a coenzyme Q analog drug candidate that it licensed from Edison Pharmaceuticals, Inc. (Edison), for inherited mitochondrial respiratory chain diseases. The Company is also applying its drug delivery technologies and drug formulation expertise to the formulation of product candidates under licensing collaborations, referred to as drug delivery technology collaborations.

Cowen and Company’s culture is rooted in the traditions of the research boutiques that once dominated the investment research landscape. Our primary focus is on two products: 1. Proprietary information flow, and 2. Good investment ideas We achieve the first objective with a combination of extensive primary research work, organized survey activity, and access to industry experts (i.e., opinion leaders in medicine, technology, and consumer industries). We believe that the best investment idea is a “Correct Non-Consensus Conclusion,” and a considerable amount of our energy is devoted to this pursuit. We spend as little time as possible on traditional maintenance research products.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/18/2007 9:25 AM Buy
as of 8/27/2015
1 Week   
1 Month   
3 Months   
1 YTD up  31.57 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy